Zealand: positive results from Part 1 of weight loss trial

 Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396

• Doses of 0.6 and 1.2 mg ZP8396 administered once-weekly for six weeks led to 5.3% and 5.1% mean weight loss as compared to 2.6%, 3.6% and 4.2% weight loss following single doses of 0.7, 1.4 and 2.4 mg ZP8396, already reported
• Part 2 investigates once-weekly dosing for 16 weeks and has been initiated, exploring significantly higher doses of ZP8396 based on the mild adverse event profile observed in Part 1 of the trial
• Results support continued development of ZP8396 as an alternative to GLP-1-based therapies for the management of overweight and obesity

https://www.biospace.com/article/releases/zealand-pharma-announces-positive-results-from-part-1-of-multiple-ascending-dose-trial-with-amylin-analog-zp8396/